Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam
versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for
fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be
included in the monotherapy branch until completing the predicted number of cases. When this
happens, the Coordinating Center will communicate it to the participant centers and from then
the patients will be included in the combined therapy.
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
PETHEMA (Program for the Study and Treatment of Haematological Malignances)
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam